Novartis: Lymphoma trials
The registry lists 20 Lymphoma studies with Novartis as lead sponsor. 2 are open to participants now and 7 have results posted.
Phase 1 14Phase 2 7Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/2
- Managed Access Programs for CTL019, TisagenlecleucelAvailableNCT03601442
- PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic MalignanciesCompletedNCT03365791Phase 2Results posted
- LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)CompletedNCT02187783Phase 2Results posted
- Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
- Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.CompletedNCT01022996Phase 2Results posted
- Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapyCompletedNCT00790036Phase 3Results posted
- Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® TherapyCompletedNCT00702052Phase 2Results posted
- A Study of Oral LBH589 in Adult Patients With Advanced Hematological MalignanciesCompletedNCT00621244Phase 1/2Results posted
- A Phase I/Ib Study of NIZ985 Alone and in Combination With SpartalizumabTerminatedNCT04261439Phase 1
- Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma PatientsTerminatedNCT03876028Phase 1
- Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedNCT03172936Phase 1
- Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple MyelomaCompletedNCT02992483Phase 1
- Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and LymphomasCompletedNCT02740270Phase 1
- Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedNCT02675439Phase 1
- A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.CompletedNCT01237236Phase 1
- Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy AdultsCompletedNCT00613665Phase 1
- A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid TumorsCompletedNCT00503451Phase 1
- A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589CompletedNCT00472368Phase 1
- Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1